PP  Vol.13 No.6 , June 2022
Study on the Preparation and Characterization of Glycyrrhizic Acid Liposomes
Abstract: The purpose of this study was to prepare glycyrrhizic acid nanoliposomes and evaluate the encapsulation efficiency and other properties of glycyrrhizic acid nanoliposomes, which would provide a reference for further research on Glycyrrhizic Acid in the treatment of liver diseases. Firstly, the preparation conditions of glycyrrhizic acid liposomes were optimized by the orthogonal design method. Then, glycyrrhizic acid liposomes were prepared by ultrasonic-film dispersion method and the encapsulation efficiency was determined by the HPLC method. Finally, the properties of glycyrrhizic acid nanoliposomes were also studied. The results showed that the optimal preparation conditions of liposomes were as follows: the ratio of drug to lipid was 1:30; Lecithin: cholesterol = 1:1; Hydration medium: pure water; Ultrasonic time: 120 s. The encapsulation efficiency of liposomes was about 90%. The final liposomes were round and uniform in distribution, with an average particle size of about 50 nm and absolute zeta potential of −28.9 mV. In this study, glycyrrhizic acid liposomes were prepared and the optimal preparation conditions were optimized. The encapsulation efficiency of the liposomes under the optimized conditions was determined. The evaluation of the morphology, size, particle size and stability of the liposomes was completed.
Cite this paper: Wang, B. , Luo, X. , Wang, J. , Jin, Y. , Wang, T. , Yu, X. and Yin, G. (2022) Study on the Preparation and Characterization of Glycyrrhizic Acid Liposomes. Pharmacology & Pharmacy, 13, 199-211. doi: 10.4236/pp.2022.136016.

[1]   Valenti, L., Aghemo, A. and Forner, A. (2019) Liver International: Anticipating the Future of Hepatology Worldwide. Liver International, 39, 1796-1797.

[2]   Berk, P.D. (1995) Hepatology and Hepatology: the Trends Continue. Hepatology, 21, 875-878.

[3]   Tandon, R.K. (2006) Journal of Gastroenterology and Hepatology: 20 Years and Gaining Momentum. Journal of Gastroenterology and Hepatology, 21, 3-5.

[4]   Teufel, A. (2015) Bioinformatics and Database Resources in Hepatology. Journal of Hepatology, 62, 712-719.

[5]   Rustgi, V.K., Davis, G.L., Herrine, S.K., McCullough, A.J., Friedman, S.L. and Gores, G.J. (2008) Future Trends in Hepatology: Challenges and Opportunities. Hepatology, 48, 655-661.

[6]   Bliuger, A.F. (1987) Sovremennye problemy klinichesko? gepatologii [Current Problems of Clinical Hepatology]. Klinicheskaia Meditsina, 65, 51-59.

[7]   Selyutina, O.Y. and Polyakov, N.E. (2019) Glycyrrhizic Acid as a Multifunctional Drug Carrier—From Physicochemical Properties to Biomedical Applications: A Modern Insight on the Ancient Drug. International Journal of Pharmaceutics, 559, 271-279.

[8]   Sun, Z.G., Zhao, T.T., Lu, N., Yang, Y.A. and Zhu, H.L. (2019) Research Progress of Glycyrrhizic Acid on Antiviral Activity. Mini Reviews in Medicinal Chemistry, 19, 826-832.

[9]   Sato, H., Goto, W., Yamamura, J., Kurokawa, M., Kageyama, S., Takahara, T., Watanabe, A. and Shiraki, K. (1996) Therapeutic Basis of Glycyrrhizin on Chronic Hepatitis B. Antiviral Research, 30, 171-177.

[10]   Chen, K., Yang, R., Shen, F.Q. and Zhu, H.L. (2020) Advances in Pharmacological Activities and Mechanisms of Glycyrrhizic Acid. Current Medicinal Chemistry, 27, 6219-6243.

[11]   Li, J.Y., Cao, H.Y., Liu, P., Cheng, G.H. and Sun, M.Y. (2014) Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review. BioMed Research International, 2014, Article ID: 872139.

[12]   Ming, L.J. and Yin, A.C. (2013) Therapeutic Effects of Glycyrrhizic Acid. Natural Product Communications, 8, 415-418.

[13]   Ling, Q., Jin, H., Zheng, J. and Shi, G. (2014) A Meta-Analysis of Diammonium Glycyrrhizinate Enteric-Coated Capsules versus Diammonium Glycyrrihizinate in Patients with Chronic Viral Hepatitis. Chinese Journal of Hepatology, 22, 411-415.

[14]   Wang, H.N., Liang, S.B., Yao, X.L., Lai, B.Y., Wen, T.Y. and Su, N. (2021) Systematic Review and Meta-Analysis of Efficacy and Safety of Compound Glycyrrhizin Injection in Improving Chronic Hepatitis B Liver Damage. China Journal of Chinese Materia Medica, 46, 694-702.

[15]   Allen, T.M. and Cullis, P.R. (2013) Liposomal Drug Delivery Systems: From Concept to Clinical Applications. Advanced Drug Delivery Reviews, 65, 36-48.

[16]   Abu Lila, A.S. and Ishida, T. (2017) Liposomal Delivery Systems: Design Optimization and Current Applications. Biological and Pharmaceutical Bulletin, 40, 1-10.

[17]   Rahman, M., Beg, S., Anwar, F., Kumar, V., Ubale, R., Addo, R.T., Ali, R. and Akhter, S. (2017) Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis. Critical Reviews in Therapeutic Drug Carrier Systems, 34, 283-316.

[18]   Zhao, Y.Z., Zhang, L., Gupta, P.K., Tian, F.R., Mao, K.L., Qiu, K.Y., Yang, W., Lv, C.Z. and Lu, C.T. (2016) Using PG-Liposome-Based System to Enhance Puerarin Liver-Targeted Therapy for Alcohol-Induced Liver Disease. AAPS PharmSciTech 17, 1376-1382.

[19]   Schwendener, R.A. and Schott, H. (2010) Liposome Formulations of Hydrophobic Drugs. Methods in Molecular Biology , 605, 129-138.

[20]   Patil, Y.P. and Jadhav, S. (2014) Novel Methods for Liposome Preparation. Chemistry and Physics of Lipids, 177, 8-18.

[21]   Yamamoto, E., Miyazaki, S., Aoyama, C. and Kato, M. (2018) A Simple and Rapid Measurement Method of Encapsulation Efficiency of Doxorubicin Loaded Liposomes by Direct Injection of the Liposomal Suspension to Liquid Chromatography. International Journal of Pharmaceutics, 536, 21-28.